Sage Therapeutics, Inc. ( SAGE ) NASDAQ Global Market

Cena: 9.25 ( -0.59% )

Aktualizacja 06-23 21:17
NASDAQ Global Market
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 487
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 82%
Ilość akcji: 60 106 700
Debiut giełdowy: 2014-07-18
WWW: https://www.sagerx.com
CEO: Mr. Barry E. Greene
Adres: 215 First Street
Siedziba: 02142 Cambridge
ISIN: US78667J1088
Opis firmy:

Sage Therapeutics, Inc., firma biofarmaceutyczna, rozwija i komercjalizuje leki w celu leczenia zaburzeń ośrodkowego układu nerwowego. Jego głównym kandydatem na produkt jest Zulresso, dożylne preparat brxanolonu w leczeniu depresji poporodowej (PPD) u dorosłych. Rurociąg firmy obejmuje również Zuranolon, neuroaktywny steryd, który jest w badaniach klinicznych fazy III w zakresie leczenia PPD, głównych zaburzeń depresyjnych, zaburzeń odpornych na leczenie, uogólnione zaburzenia lękowe i depresję dwubiegunową; oraz SAGE-324, związek, który jest w badaniu klinicznym fazy II w celu leczenia niezbędnych wstrząsów, a także zakończyło badanie kliniczne fazy I w sprawie epilepsji i chorób Parkinsona. Ponadto jego rurociąg produktów obejmuje SAGE-718, dodatni allosteryczny modulator allosteryczny oparty na oksysterolu receptora NMDA, który zakończył badanie kliniczne fazy I w leczeniu depresji, choroby Huntingtona, choroby Alzheimera, zaburzenia nadaktywności w odniesieniu do uwagi, schizofrenii i bólu neuropatycznego. Sage Therapeutics, Inc. prowadzi strategiczną współpracę z Shionogi & Co., Ltd. w zakresie rozwoju i komercjalizacji Zuranolone w Japonii, Tajwanie i Korei Południowej; oraz umowa o współpracy i licencji z Biogen MA Inc. w celu wspólnego opracowania i komercjalizacji produktów SAGE-217 i SAGE-324. Firma była wcześniej znana jako Sterogen Biopharma, Inc. i zmieniła nazwę na Sage Therapeutics, Inc. we wrześniu 2011 r. Sage Therapeutics, Inc. został zarejestrowany w 2010 roku i ma siedzibę w Cambridge, Massachusetts.

Wskaźniki finansowe
Kapitalizacja (USD) 578 949 426
Aktywa: 622 432 000
Cena: 9.25
Wskaźnik Altman Z-Score: -4.3
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.6
Ilość akcji w obrocie: 82%
Średni wolumen: 1 520 004
Ilość akcji 62 622 300
Wskaźniki finansowe
Przychody TTM 106 399 000
Zobowiązania: 70 597 000
Przedział 52 tyg.: 4.62 - 13.47
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -5.8
P/E branży: 26.1
Beta: 0.924
Raport okresowy: 2025-07-29
WWW: https://www.sagerx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Laura Gault M.D., Ph.D. Chief Medical Officer 890 938 1969
Mr. Christopher Benecchi Chief Business Officer 677 244 1972
Ms. Anne Marie Cook Esq. Senior Vice President, General Counsel & Secretary 673 656 1962
Ms. Kimi E. Iguchi CPA Chief Financial Officer & Treasurer 659 608 1962
Mr. Barry E. Greene President, Chief Executive Officer & Director 1 242 626 1963
Ashley Kaplowitz Director of Investor Relations 0 0
Ms. Erin E. Lanciani Chief People & Experience Officer 0 1969
Mr. Mike Quirk Ph.D. Chief Scientific Officer 0 0
Mr. Matt Lasmanis Chief Technology & Innovation Officer 0 0
Dr. Amy Schacterle Ph.D. Senior Vice President of R&D Strategy and Business Management 0 0
Wiadomości dla Sage Therapeutics, Inc.
Tytuł Treść Źródło Aktualizacja Link
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-15 14:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-13 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-11 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-08 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-06 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-04 14:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-05-01 14:00:00 Czytaj oryginał (ang.)
Tetra Tech to Advance Its Digital Automation Solutions with the Acquisition of SAGE Group PASADENA, Calif.--(BUSINESS WIRE)-- #digitalautomation--Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that it has signed a definitive agreement to acquire SAGE Group Holdings Ltd (SAGE Group), a premier automation solutions provider known for its expertise in municipal water and industrial manufacturing automation, smart infrastructure, and systems integration. SAGE Group delivers innovative. businesswire.com 2025-05-01 13:00:00 Czytaj oryginał (ang.)
Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae. zacks.com 2025-04-30 17:20:44 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call Transcript Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q1 2025 Earnings Call April 29, 2025 4:30 PM ET Company Participants Ashley Kaplowitz - Investor Relations Barry Greene - Chief Executive Officer Chris Benecchi - Chief Operating Officer Mike Quirk - Chief Scientific Officer and Interim Head, R&D Conference Call Participants Malcolm Kuno - JPMorgan Shrunatra Mishra - Goldman Sachs Morgan Gryga - Morgan Stanley Ami Fadia - Needham Brian Abrahams - RBC Capital Markets David Amsellem - Piper Sandler Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Joel Beatty - Baird Laura Chico - Wedbush Securities Basma Radwan - Leerink Partners Sumant Kulkarni - Canaccord Asim Rana - Truist Securities Operator Good afternoon. seekingalpha.com 2025-04-30 02:33:29 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.99. This compares to loss of $1.80 per share a year ago. zacks.com 2025-04-29 22:20:37 Czytaj oryginał (ang.)
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025. “We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team's disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “We remain focused on establi. businesswire.com 2025-04-29 20:05:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-29 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-24 14:00:00 Czytaj oryginał (ang.)
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm NEW YORK , April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Sage Therapeutics, Inc. (NASDAQ: SAGE)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Sage insiders caused the company to misrepresent or fail to disclose that (i) zuranolone was less effective in treating MDD than the company had led investors to believe; (ii) accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone's clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated; (iii) SAGE-718 was less effective in treating MCI due to PD than the company had led investors to believe; (iv) accordingly, SAGE-718's clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated; (v) SAGE-324 was less effective in treating ET than the company had led investors to believe; (vi) accordingly, SAGE-324's clinical, regulatory, and commercial prospects as a treatment for ET were overstated; and (vii) as a result of all the foregoing, the company's public statements were materially false and misleading at all relevant times. prnewswire.com 2025-04-22 20:16:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-22 15:05:52 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-22 14:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-20 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-17 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-04-15 14:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Shareholders to Reach Out NEW YORK CITY, NY / ACCESS Newswire / February 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-14 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-13 12:00:00 Czytaj oryginał (ang.)
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y SAGE's earnings and revenues miss estimates in the fourth quarter of 2024. The company focuses on the commercialization of depression drug Zurzuvae. zacks.com 2025-02-12 14:46:18 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-12 12:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Q4 2024 Earnings Call Transcript Start Time: 16:30 January 1, 0000 5:19 PM ET Sage Therapeutics, Inc. (NASDAQ:SAGE ) Q4 2024 Earnings Conference Call February 11, 2025, 16:30 PM ET Company Participants Barry Greene - CEO Chris Benecchi - COO Laura Gault - CMO Mike Quirk - CSO Ashley Kaplowitz - VP, IR and Capital Markets Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JPMorgan Paul Matteis - Stiefel Tazeen Ahmad - Bank of America Ami Fadia - Needham Douglas Tsao - H.C. Wainwright Uy Ear - Mizuho Joel Beatty - Baird Sumant Kulkarni - Canaccord Joon Lee - Truist Securities Operator Good afternoon. seekingalpha.com 2025-02-11 23:29:05 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.45. This compares to loss of $0.55 per share a year ago. zacks.com 2025-02-11 20:21:24 Czytaj oryginał (ang.)
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is being recognized as an important treatment option for women with postpartum depression and we believe it will continue to be instrumental in accelerating progress in maternal mental health,” said Barry Greene,. businesswire.com 2025-02-11 18:05:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Shareholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / February 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-11 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-10 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / February 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-09 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-07 12:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-06 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / February 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-05 12:00:00 Czytaj oryginał (ang.)
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-02-04 13:05:25 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-04 12:00:00 Czytaj oryginał (ang.)
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-03 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / February 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-02-02 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-01-31 12:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sage Therapeutics, Inc. (SAGE) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / January 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SAGE. accessnewswire.com 2025-01-30 12:30:00 Czytaj oryginał (ang.)
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value. zacks.com 2025-01-28 14:56:10 Czytaj oryginał (ang.)